- Home
- GBR vs PPBT Comparison
GBR vs PPBT Comparison
Compare GBR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | PPBT |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.4M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GBR | PPBT |
|---|---|---|
| Price | $0.78 | $3.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 130.3K | 5.3K |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.65 | $0.41 |
| 52 Week High | $1.78 | $5.18 |
Technical Indicators
Market Signals| Indicator | GBR | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 43.38 |
| Support Level | $0.74 | $3.70 |
| Resistance Level | $0.88 | $4.39 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 30.25 | 29.29 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.